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BK VIRUS NEPHROPATHY IN A HEART TRANSPLANT RECIPIENT: 
THE FIRST DOCUMENTED CASE IN CROATIA
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As outcomes following heart transplantation have improved significantly over the last years, chronic kidney 
disease has become an increasingly prevalent complication in this population. Polyomavirus-associated ne-
phropathy (PVAN) of native kidneys has also been recognized increasingly as a cause of kidney failure. We 
report the first case of PVAN occurring in the native kidneys of a solid-organ transplant recipient in Croatia 
as the eighth case described in the literature worldwide. A 65-year-old female with dilatative cardiomyopathy 
and good kidney function had a heart transplanted in 2012. Initial immunosuppressive therapy consisted 
of antithymocyte immunoglobulin with cyclosporine, mycophenolate mofetil and corticosteroids. Soon after 
transplantation, her kidney function began to fail progressively. Biopsy of the native kidneys revealed PVAN, 
and everolimus was introduced in immunosuppressive therapy. Nevertheless, her renal dysfunction pro-
gressed and she is now being evaluated for cadaveric kidney transplantation. PVAN should be considered 
in the differential diagnosis of new-onset renal failure following non-kidney solid organ transplantation. Early 
diagnosis is essential for prevention of irreversible renal damage.
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INTRODuCTION
Polyomavirus-associated nephropathy (PVAN) is a well-
recognized cause of renal allograft dysfunction and allo-
graft loss in renal transplant recipients, but it is an infre-
quent cause of nephropathy outside this setting. However, 
as outcomes following heart transplantation have improved 
significantly over the last years, chronic kidney disease 
(CKD) has become an increasingly prevalent complica-
tion in this population(1) and the number of PVAN of native 
kidneys reported in the literature is growing. We report 
the first case of PVAN occurring in the native kidneys of 
a solid-organ transplant recipient in Croatia as the eighth 
case described in the literature worldwide. 
CASE REPORT
A female Caucasian patient born in 1940 was diagnosed 
with dilatative cardiomyopathy of unknown origin in 
2011. Over a 2-year interval, she developed progressive 
congestive heart failure and due to deteriorating condition 
she underwent orthotopic cardiac transplantation on De-
cember 14, 2012. She had no concomitant illnesses and a 
good kidney function at the time of transplantation, with 
creatinine clearance 75-80 mL/min and proteinuria 0.31g/
day. unfortunately, data on kidney imaging studies done 
before transplantation were lost during the years. We can 
only presume that it was satisfactory. 
Yet, kidney function is difficult to assess in patients with 
HF because they are frequently malnourished with low 
muscle mass and have edema. A normal or near normal 
serum creatinine level in this population does not neces-
sarily reflect normal kidney function. 
The degree of renal functional impairment posttransplant 
and the rate of CKD progression greatly depend on the 
extent of pretransplant kidney functional impairment, but 
also on the intra- and early postoperative course, the im-
munosuppressive regimen and individual clinical features 
that determine susceptibility to renal injury (patient age, 
presence of pretransplant diabetes and hypertension). 
Table 1
Proposition for kidney function assessment prior to orthotopic heart transplantation
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The transplantation and immediate postoperative course 
were uneventful. Induction therapy included antithymo-
cyte immunoglobulin with cyclosporine, mycophenolate 
mofetil (MMF) and corticosteroids. Serum creatinine im-
mediately after transplantation was stable around 87-95 
μmol/L. Four months after transplantation, the patient’s 
kidney function began to deteriorate progressively with-
out new-onset proteinuria or erythrocyturia. Cardiologist 
presumed that worsening of kidney function was due to 
calcineurin nephrotoxicity and in an attempt to reduce it 
10 months after transplantation, the patient was switched 
from cyclosporine to tacrolimus. However, renal function 
continued to deteriorate further. Two years after trans-
plantation, a nephrologist was consulted for the first time. 
Imaging studies revealed shrunken, chronically damaged 
kidneys with creatinine clearance of 35 mL/min and pro-
teinuria 0.15 g/day. Also, BK viremia with 68,500 copies/
mL was discovered. Biopsy of the native kidneys showed 
renal tubular cells with intranuclear inclusions character-
istic of PVAN. Immunohistochemical staining for SV40 
large T showed strong nuclear positivity in many distal tu-
bular and collecting duct epithelial cells, which confirmed 
the diagnosis.
The patient had a stable heart function until that time, 
without any signs of rejection on repeated surveillance 
heart biopsies. Considering that, we decided to reduce im-
munosuppressive therapy by switching from tacrolimus to 
everolimus. unfortunately, in a few days, the combination 
of everolimus with MMF and corticosteroids resulted in 
severe leukopenia that did not recover after reduction of 
MMF dose. Immunosuppression was changed again to 
tacrolimus with everolimus and corticosteroids while aim-
ing at low levels (around 4 μg/L both). 
After six months, the BK virus blood level fell to 1125 
copies/mL, but renal dysfunction progressed further. Her 
creatinine clearance is now 13-10 mL/min and, as her heart 
function and overall clinical status is good, she is under 
evaluation for cadaveric kidney transplantation.
DISCuSSION
Chronic kidney disease and end-stage heart failure (HF) 
share multiple traditional risk factors such as hyperten-
sion, diabetes mellitus, and chronic glomerular ischemia 
due to poor renal perfusion. No wonder that up to one-
third of all patients with New York Heart Association 
stage 3 or 4 end-stage HF have also evidence of CKD(2). 
However, data on the evaluation of kidney function prior 
to orthotopic heart transplant are less well defined than 
liver transplant candidates and no formal guidelines ex-
ist. The objective of pretransplant evaluation is to establish 
the likelihood of being left with adequate kidney function 
after transplantation and the chance of progression to end-
stage renal disease (Tablica 1).
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Table 1. Proposition for kidney function assessment prior to orthotopic heart transplantation
Evaluation of kidney function prior to orthotopic heart transplantation 
Complete patient history 
Physical examination 
Creatinine clearance 
Total urinary protein excretion 
Urinalysis 
Urine culture 
Kidney ultrasound (and color Doppler of renal arteries if necessary) 
Kidney biopsy (if necessary) 
 The majority of cardiac transplant recipients will develop 
CKD within the first year after transplantation. They usu-
ally suffer an initial, rapid decline in renal function in the 
first two years posttransplant, which is followed by a less 
pronounced decline afterwards(3). The mechanism under-
lying this biphasic pattern seems to be different kidney 
response to early versus late injuries. 
Early after transplantation, kidney is exposed to peri-
operative and postoperative insults (surgical issues and 
complications, infections, etc.) and effect of calcineurin 
inhibitor therapy. After that, renal function stabilizes. 
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It seems that kidney function at the end of the first year 
posttransplant reflects renal function reserve and also 
predicts long-term renal outcome and mortality(4).
Late posttransplant kidney injury is a result of ongoing 
renal insults that accumulate from the traditional CKD 
risk factors (hypertension, new-onset diabetes after trans-
plantation, and dyslipidemia)(5), and nephrotoxic effects 
of immunosuppressive drugs such as calcineurin inhibi-
tors (CNI) (cyclosporine and tacrolimus) and mammalian 
target of rapamycin (mTOR) inhibitors (sirolimus and 
everolimus)(6). Chronic CNI injury, clinically manifested 
by increased serum creatinine, sub-nephrotic range pro-
teinuria, and bland urine sediment, is present in the ma-
jority of long-surviving, nonrenal transplant recipients. 
Kidney biopsy studies demonstrate histologic changes 
consistent with long-term CNI nephrotoxicity in 60%-
70% of heart and liver transplant recipients with post-
transplant end-stage renal disease(7). Apart from direct 
nephrotoxic and hemodynamic effects that CNI cause 
through inhibition of nitric oxide and alterations in the 
RAAS(8), CNI, as also m-TOR inhibitors, cause metabolic 
changes (diabetes, hyperlipidemia, and hypertension) that 
contribute to development of kidney injury(9,10). mTOR-in-
hibitors also promote development of anemia, potentiate 
CNI nephrotoxicity, and in some patients cause develop-
ment of new-onset proteinuria(11). 
There are several approaches to reducing CNI nephro-
toxicity. The dose of CNI can be reduced with the ad-
dition of MMF, resulting in long-term renal functional 
improvement(12). If the patient is taking cyclosporine, it 
can be switched to tacrolimus, as described in our case 
report. There are single-center case series, registry analy-
ses, and multicenter studies demonstrating the benefit 
of tacrolimus over cyclosporine in both conversion and 
de novo heart settings(13). Third strategy involves utiliza-
tion of regimens that completely eliminate CNI with the 
introduction of m-TOR inhibitors. In some nonrenal or-
gan recipients, while the elimination or minimization of 
calcineurin inhibitors has been associated with mild im-
provement in kidney function, this has often come at the 
expense of compromised immunosuppressive efficacy 
and worse patient outcomes(14).
Nephrotoxicity of CNI appears to be the major histologic 
feature in heart transplant recipients, but such injury may 
be indistinguishable from other unrelated kidney inju-
ries such as chronic ischemia changes associated with 
atherosclerotic vascular disease(15) or PVAN(16,17). PVAN is 
caused primarily by BK virus (BKV), but JC virus (JCV) 
and possibly simian virus SV40 may account for some 
cases. BKV is widely spread among people; however, it 
is clinically significant only in immunocompromised pa-
tients. Primary infection occurs most frequently in child-
hood and is usually innocent, but the virus stays latent 
in lymphoid cells and kidney epithelial cells (transitional, 
tubular and parietal cells of Bowman capsule). The most 
important risk factor for development of PVAN is the lev-
el of immunosuppression and some consider development 
of BKV replication a clear sign of too high level of immu-
nosuppression. Various combinations of immunosuppres-
sive drugs have been linked with development of PVAN; 
however, we still lack clear evidence for this connection. 
PVAN has been proven in patients receiving almost every 
possible immunosuppressive drugs or their combination. 
Besides immunosuppressive drugs, risk factors for devel-
opment of PVAN are older or younger age, male gender, 
CMV infection, acute rejection treatment, white race and 
use of corticosteroids. 
Polyomavirus-associated nephropathy appears to be a 
rare cause of renal failure in heart transplant recipients 
with only eight cases published in the literature, but is it 
really so? Renal biopsy is the gold standard for diagnos-
ing PVAN(18) and also the only method to distinguish it 
from CNI nephrotoxicity. However, the high incidence of 
CNI nephrotoxicity in heart transplant recipients has led 
to a common assumption that every renal failure in this 
population can be attributed to CNI toxicity, without re-
nal histopathologic evaluation. This assumption leads to 
changes in immunosuppression that can further worsen 
PVAN and cause unnecessary delay in establishing the 
true cause of renal failure. PVAN should be considered 
in the differential diagnosis when evaluating worsening 
kidney function after heart transplantation and a more 
proactive approach in search for the cause of kidney fail-
ure could result in a higher prevalence of PVAN in this 
patient population. 
Treatment of PVAN remains a problem. It is based on 
the adjustment of immunosuppressive regimens and the 
empiric use of adjuvant antiviral therapy. unfortunately, 
treatment is very often ineffective and preventive screen-
ing for BKV replication and empiric reduction of immu-
nosuppression is still the preferred approach(19). However, 
BKV replication surveillance studies of non-kidney sol-
id-organ recipients are lacking and the value of regular 
monitoring of BKV replication in non-kidney transplant 
recipients is still not clear.
CONCLuSION
Kidney injury in heart transplant recipients is a common 
problem with serious consequences. Active approach 
should be taken in establishing the cause of kidney fail-
ure and PVAN should be considered in differential diag-
nosis. We need more studies to determine the value of 
regular monitoring for BKV replication in heart trans-
plant recipients. 
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Unazad nekoliko godina sa značajnim poboljšanjem preživljenja bolesnika s transplantiranim srcem kronično 
zatajenje bubrega postalo je sve češća komplikacija u toj populaciji. Nefropatija uzrokovana poliomaviru-
som (PVAN) nativnih bubrega također se sve češće prepoznaje kao uzrok zatajenja bubrega. Prikazujemo 
prvi slučaj PVAN nativnih bubrega kod primatelja transplantata solidnog organa u Hrvatskoj i osmi takav 
slučaj dosad opisan u literaturi. Bolesnici u dobi od 65 godina s dilatativnom kardiomiopatijom i dobrom 
bubrežnom funkcijom je 2012. godine transplantirano srce. Inicijalna imunosupresivna terapija sastojala se 
od antitimocitnog imunoglobulina s ciklosporinom, mikofenolat mofetilom i kortikosteroidima. Ubrzo nakon 
transplantacije dolazi do zatajenja bubrega. Biopsijom nativnih bubrega postavljena je dijagnoza PVAN, a 
u imunosupresivnu terapiju je uveden everolimus. Usprkos tome dolazi do daljnjeg napredovanja zatajenja 
bubrega i bolesnica je trenutno u pripremi za kadaveričnu transplantaciju bubrega. PVAN treba razmotriti u 
diferencijalnoj dijagnozi novonastalog zatajenja bubrega nakon transplantacije solidnih organa. Rana dija-
gnoza PVAN je bitna u sprječavanju razvoja ireverzibilnog bubrežnog zatajenja.
Ključne riječi: poliomavirusna nefropatija, transplantacija srca, zatajivanje bubrega
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